This product is a recombinant mouse antibody that recognizes VEGFA. G6-31 recognises a VEGF epitope which is conserved between human and mouse VEGF and overlaps with the receptor binding surface.
Figure 1 Assessment of G6–31 activity against lung lesions when administrated intraperitoneally.
(A) Experimental procedure; Four month-old K-rasLA1 mice received G6–31 or an isotype control, administrated by i.p injection or aerosol, once a week for 4 wk. At the time of death visible lesions were counted on the whole lungs. (B) Quantification of visible nodules per mouse (n = 15 mice per group; 2.5 mg/kg and 10 mg/kg; *P< 0.05 Mann-Whitney test). Results are expressed as the mean ± SEM of nodules. (C) Quantification of lung lesions on H&E stained sections from control and G6–31 treated group (n = 15 mice per group; 2.5 mg/kg and 10 mg/kg; P< 0.05 Mann-Whitney test). Results are expressed as the mean ± SEM of the number of lesions.
Hervé, V., Rabbe, N., Guilleminault, L., Paul, F., Schlick, L., Azzopardi, N., ... & Paintaud, G. (2014, November). VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-ras activating-mutations. In MAbs (Vol. 6, No. 6, pp. 1638-1648). Taylor & Francis.
Figure 2 Assessment of aerosolized G6–31 activity against lung lesions.
(A) Quantification of visible nodules per mouse (n = 15 mice per group; 2.5 mg/kg and 10 mg/kg; *P < 0.05 Mann-Whitney test). Results are expressed as the mean ± SEM of nodules. (B) Quantification of lung lesions on H&E stained sections from control and G6–31 treated group (n =15 mice per group; 2.5 mg/kg and 10 mg/kg; P < 0.05 Mann-Whitney test). Results are expressed as the mean ± SEM of the number of lesions.
Hervé, V., Rabbe, N., Guilleminault, L., Paul, F., Schlick, L., Azzopardi, N., ... & Paintaud, G. (2014, November). VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-ras activating-mutations. In MAbs (Vol. 6, No. 6, pp. 1638-1648). Taylor & Francis.
Figure 3 Effect of G6–31 at 10 mg/kg administered by i.p. injection or aerosol on K-ras LA1 lung tumors according to each lesion type and effect on microvascular density.
(A) Quantification of AAH (atypical alveolar hyperplasia), Ad (adenoma) and ADC (adenocarcinoma), on H&E stained lung sections from control and G6–31-treated (10 mg/kg dose) mice (n = 30 mice per group; *P < 0.05 Mann-Whitney test). Results are expressed as the mean ± SEM of the number of each lesion type. (B) Representative image of vWFimmunostaining in the lung of K-ras LA1 mice. Bold arrow shows large vessel while standard arrow shows small vessel. (C) Quantification of the microvascular density, from vWFimmunostaining in control and G6–31-treated (10 mg/kg dose) mice (n = 30 mice per group; *P < 0.05 Mann-Whitney test). Results are expressed as the mean ± SEM.
Hervé, V., Rabbe, N., Guilleminault, L., Paul, F., Schlick, L., Azzopardi, N., ... & Paintaud, G. (2014, November). VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-ras activating-mutations. In MAbs (Vol. 6, No. 6, pp. 1638-1648). Taylor & Francis.
Figure 4 Detection of PCNA by western blotting in whole lung protein extracts from control mice (mice 1–4) and G6–31-treated (10 mg/kg) mice (mice 5–9).
Pulmonary delivery is on the right and i.p. delivery is on the left.
Hervé, V., Rabbe, N., Guilleminault, L., Paul, F., Schlick, L., Azzopardi, N., ... & Paintaud, G. (2014, November). VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-ras activating-mutations. In MAbs (Vol. 6, No. 6, pp. 1638-1648). Taylor & Francis.
Figure 5 CC-3 immunostaining.
Representative images of the control (left) and G6–31 (10 mg/kg dose) delivered either by i.p. (middle) or by pulmonary route (right). Brown cells are positive for CC-3 (arrows show some representative cells). The slices were counterstained with hematoxylin (× 400 magnification).
Hervé, V., Rabbe, N., Guilleminault, L., Paul, F., Schlick, L., Azzopardi, N., ... & Paintaud, G. (2014, November). VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-ras activating-mutations. In MAbs (Vol. 6, No. 6, pp. 1638-1648). Taylor & Francis.
Figure 6 Quantification of apoptosis in tumor lesions of the right lung of K-ras LA1 mice (n = 15 mice per group; *P < 0.05 Mann-Whitney test).
Results are expressed as the mean staining scores of CC-3 positive cells relative to the control group ± SEM.
Hervé, V., Rabbe, N., Guilleminault, L., Paul, F., Schlick, L., Azzopardi, N., ... & Paintaud, G. (2014, November). VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-ras activating-mutations. In MAbs (Vol. 6, No. 6, pp. 1638-1648). Taylor & Francis.
Figure 7 Blockade of VEGFR2 signaling pathway.
Phospho-VEGFR2 Y1175, total VEGFR2, Phospho-PI3K, b-actin, Phospho-AKT, total AKT, Phospho-ERK and total ERK were analyzed by western blotting in whole lung protein extracts from control mice (mice 1–4) and from mice treated with G6–31 at 10 mg/kg (mice 5–9). Pulmonary delivery is on the right and i.p. delivery is on the left.
Hervé, V., Rabbe, N., Guilleminault, L., Paul, F., Schlick, L., Azzopardi, N., ... & Paintaud, G. (2014, November). VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-ras activating-mutations. In MAbs (Vol. 6, No. 6, pp. 1638-1648). Taylor & Francis.
Figure 8 Pharmacokinetics of G6–31.
Serum concentration of G6–31 mAb was measured by ELISA in the serum collected at different time points from mice that received a single dose of the mAb (10 mg/kg) either by the pulmonary route (left, n = 13) or intravenously (right, n = 15). Gray area and solid line show the 5th-95th and 50th percentiles of the model-predicted time-concentration profiles, respectively.
Hervé, V., Rabbe, N., Guilleminault, L., Paul, F., Schlick, L., Azzopardi, N., ... & Paintaud, G. (2014, November). VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-ras activating-mutations. In MAbs (Vol. 6, No. 6, pp. 1638-1648). Taylor & Francis.
Figure 9 Mab G6-31 treated Drd2-/- female mice.
A) Pituitary weight in vehicle (N=5) and Mab G6-31 treated (N=7) Drd2-/- female mice, * p <0.05 vs vehicle Drd2-/- treated mice. B) Serum prolactin levels in female Drd2-/- vehicle (N=5) or Drd2-/- Mab G6-31 treated mice (N=7). C) Pituitary prolactin concentration (ng/gland) in control Drd2-/-, Mab G6-31 treated Drd2-/- and wild-type (WT) female mice (N=5, 5 and 5, respectively). D) Percent of prolactin positive area by confocal immunohistochemistry in control Drd2-/- and Mab G6-31 treated Drd2-/- and wild-type (WT) female mice (N=6, 7 and 5 respectively), * p<0.05 vs. Drd2-/- vehicle treated mice.
Luque, G. M., Perez-Millán, M. I., Ornstein, A. M., Cristina, C., & Becu-Villalobos, D. (2011). Inhibitory effects of antivascular endothelial growth factor strategies in experimental dopamine-resistant prolactinomas. Journal of Pharmacology and Experimental Therapeutics, 337(3), 766-774.
Figure 10 Percent of PCNA stained cells (positive PCNA nuclei X 100/ total nuclei) evaluated by immunohistochemistry in control Drd2-/-, Mab G6-31 treated Drd2-/-, and wild-type (WT) female mice (N=6, 6 and 4 respectively), * p <0.05 vs. Drd2-/- vehicle treated mice.
Luque, G. M., Perez-Millán, M. I., Ornstein, A. M., Cristina, C., & Becu-Villalobos, D. (2011). Inhibitory effects of antivascular endothelial growth factor strategies in experimental dopamine-resistant prolactinomas. Journal of Pharmacology and Experimental Therapeutics, 337(3), 766-774.
Shen, Jingjing, et al. "Eyedrop-based macromolecular ophthalmic drug delivery for ocular fundus disease treatment." Science advances 9.4 (2023): eabq3104.
This study focuses on developing an innovative delivery system for macromolecular ophthalmic drugs to treat ocular fundus diseases using eyedrop formulations. Traditional treatments like intravitreal injections present risks such as infections and retinal detachment. This research introduces a penetrating carrier based on fluorocarbon-modified chitosan (FCS), which can self-assemble with proteins to form nanocomplexes. These nanocomplexes effectively traverse ocular barriers to reach the posterior eye segments, demonstrating superior therapeutic responses in mouse models of choroidal melanoma and choroidal neovascularization compared to conventional methods. The FCS/anti-PDL1 and FCS/anti-VEGFA eyedrops induced stronger antitumor immune responses and inhibited vascular proliferation, respectively, showcasing the potential for at-home treatment of various eye diseases.
In this study, Creative Biolabs provided crucial therapeutic antibodies that were integral to the research. Specifically, they supplied anti-VEGFA (Cat#: HPAB-0330CQ), which was used in the formulation of FCS/anti-VEGFA nanocomplexes for treating choroidal neovascularization. This antibody played a pivotal role in achieving comparable therapeutic effects to intravitreal injections, thus validating the efficacy of the new delivery system. The contributions of Creative Biolabs significantly advanced the study, highlighting the potential for noninvasive, effective treatment options for ocular diseases.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-H73 | Anti-Human VEGFA Recombinant Antibody (Vanucizumab) | WB, FC, IP, ELISA, Neut, FuncS, IF | VH - C-kappa - CH2 - CH3 _ V-lambda - CH1 _ H-GAMMA-1 _ L-kappa |
TAB-011 | Anti-Human VEGF Recombinant Antibody (Bevacizumab) | FC, IP, ELISA, Neut, FuncS, IF, ICC | IgG1 - kappa |
TAB-012-F(E) | Anti-Human VEGF Recombinant Antibody Fab Fragment (Ranibizumab) | IP, IF, FuncS, FC, Neut, ELISA, IHC | Fab - G1 - kappa |
TAB-307CQ-S(P) | Human Anti-VEGFA Recombinant Antibody; scFv Fragment (TAB-307CQ-S(P)) | ELISA, Neut | Human scFv |
TAB-009ML | Anti-Human VEGFA Recombinant Antibody scFv Fragment (Brolucizumab) | ELISA, IHC, FC, IP, IF, Inhib | scFv, κ |
To accurately reference this product in your publication, please use the following citation information:
(Creative Biolabs Cat# HPAB-0330CQ, RRID: AB_3111386)
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.